Chemical compound lights up treatment-resistant cancers on imaging scans

Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that could help medical professionals better target and treat cancer.

Eli Lilly’s Zepbound eases obstructive sleep apnea in trials

Eli Lilly reported positive results of its obesity drug Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity

April 17, 2024

GSK steps in for J&J’s license of Arrowhead’s hepatitis B drug, plans combo study with its own candidate

British drugmaker GSK plans to acquire an experimental hepatitis B drug from Johnson & Johnson and its developer Arrowhead Pharmaceuticals and then combine the siRNA

November 1, 2023

Wall Street: GLP-1 competitors’ pain is Eli Lilly’s gain

Eli Lilly’s stock continued its wild ride Wednesday after lackluster data from Amgen’s potential GLP-1 competitor further demonstrated tirzepatide’s advantage. On Wednesday, Lilly shares $LLY

February 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.